X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs MERCK LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA MERCK LTD GSK PHARMA/
MERCK LTD
 
P/E (TTM) x 64.6 35.0 184.7% View Chart
P/BV x 10.4 3.9 265.0% View Chart
Dividend Yield % 1.2 0.7 168.9%  

Financials

 GSK PHARMA   MERCK LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
MERCK LTD
Dec-16
GSK PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs3,8381,060 362.1%   
Low Rs2,637623 423.3%   
Sales per share (Unadj.) Rs354.2632.4 56.0%  
Earnings per share (Unadj.) Rs39.845.7 87.0%  
Cash flow per share (Unadj.) Rs42.962.3 68.8%  
Dividends per share (Unadj.) Rs30.0011.00 272.7%  
Dividend yield (eoy) %0.91.3 70.9%  
Book value per share (Unadj.) Rs236.9388.8 60.9%  
Shares outstanding (eoy) m84.7016.60 510.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.11.3 687.0%   
Avg P/E ratio x81.418.4 442.3%  
P/CF ratio (eoy) x75.513.5 559.2%  
Price / Book Value ratio x13.72.2 631.4%  
Dividend payout %75.424.1 313.6%   
Avg Mkt Cap Rs m274,21613,969 1,963.0%   
No. of employees `0004.71.6 296.7%   
Total wages/salary Rs m4,8301,487 324.9%   
Avg. sales/employee Rs Th6,387.06,631.9 96.3%   
Avg. wages/employee Rs Th1,028.3939.2 109.5%   
Avg. net profit/employee Rs Th717.1479.4 149.6%   
INCOME DATA
Net Sales Rs m30,00010,498 285.8%  
Other income Rs m728242 300.4%   
Total revenues Rs m30,72810,741 286.1%   
Gross profit Rs m4,1901,135 369.0%  
Depreciation Rs m263276 95.5%   
Interest Rs m00-   
Profit before tax Rs m4,6551,102 422.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744343 508.0%   
Profit after tax Rs m3,368759 443.8%  
Gross profit margin %14.010.8 129.1%  
Effective tax rate %37.531.1 120.3%   
Net profit margin %11.27.2 155.3%  
BALANCE SHEET DATA
Current assets Rs m16,7426,410 261.2%   
Current liabilities Rs m7,2028,828 81.6%   
Net working cap to sales %31.8-23.0 -138.0%  
Current ratio x2.30.7 320.2%  
Inventory Days Days5258 89.8%  
Debtors Days Days2138 54.1%  
Net fixed assets Rs m8,6351,406 614.0%   
Share capital Rs m847166 510.2%   
"Free" reserves Rs m19,2226,286 305.8%   
Net worth Rs m20,0696,455 310.9%   
Long term debt Rs m100-   
Total assets Rs m30,0388,828 340.3%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.01.2 84.0%   
Return on assets %11.28.6 130.4%  
Return on equity %16.811.8 142.7%  
Return on capital %25.517.1 149.1%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m528959 55.1%   
Fx outflow Rs m7,1932,612 275.4%   
Net fx Rs m-6,665-1,653 403.2%   
CASH FLOW
From Operations Rs m2,3601,070 220.5%  
From Investments Rs m3,008-750 -401.2%  
From Financial Activity Rs m-5,108-150 3,409.6%  
Net Cashflow Rs m260171 152.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 51.8 97.9%  
Indian inst/Mut Fund % 10.2 18.2 56.0%  
FIIs % 23.8 1.0 2,380.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 29.1 52.9%  
Shareholders   102,036 28,591 356.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  ELDER PHARMA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Crash in Bitcoin, Correction in MidCap and SmallCap Indices and Top Stocks in Action Today(Pre-Open)

The past year has seen the BSE MidCap and BSE SmallCap indices surging by 43.1% and 57.1% respectively. Taking a two year view these indices have produced mind-boggling return of 75.3% .

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 16, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS